Health care technology company Aetion reported on Tuesday that it has entered into a partnership with the US Food & Drug Administration (FDA) and Brigham and Women's Hospital/Harvard Medical School to apply the Aetion Evidence Platform in exploring the potential of real-world analyses in advancing regulatory process for critical treatments.
This landmark study aims to demonstrate the value of RWE (real-world evidence) as an accelerant to drug approval, particularly for supplemental indications. Aetion's software platform will re-create randomized clinical trials (RCTs) through real-world evidence (RWE).
Under the 21st Century Cures Act and Prescription Drug User Fee Act VI, the US FDA-sponsored research study employs the Aetion Evidence Platform at replicating the results of 30 published RCTs, to see whether the use of RWE would have led to the same regulatory decisions. The results will demonstrate whether RWE could be used to supplement or, in certain circumstances, even replace clinical trials for drug development and regulatory approval.
Of the 30 trials to be replicated (cardiovascular, endocrinology, musculoskeletal and pulmonary), 23 involved positive decisions, added the partnership.
The three-year study began in fall 2017 and is funded by the US FDA's Center for Drug Evaluation and Research and is led by the Office of Medical Policy.
Additionally, the Aetion Evidence Platform uses the everyday clinical and financial interactions of the health care system to unlock essential evidence about the effectiveness and value of treatments. Its validated, rapid-cycle analytics allows users to significantly reduce "time to evidence" and improve patient outcomes.
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist